Subject Index

- 5-Methylcytosine (5mC)
 about, 1
 biological functions of 5hmC, 4–5
 biological functions of TET proteins, 4
 conclusions, 7–8
 detection and mapping of 5mC and oxi-mC
 affinity approaches, 5–6
 sequencing depth's effect on mapping performance, 7
 single-nucleotide resolution approaches, 6–7
 distribution mapping of, 1
 gene expression in T cells and, 5
 relationship to DNMTs, 1
 TET proteins and generation of 5mC oxidases, 1–2
 TET proteins and oxi-mC
 active DNA methylation through DNA repair, 3–4
 demethylation pathways and, 2–3
 passive dilution of the oxidized base during replication, 3
- A**
- ACh (acetylcholine), 142, 145–146
 Affinity approaches to mapping 5mC, 5–6
 Ag (antigen) valency and BCR activation, 232–234. *See also* B-cell receptor (BCR) signaling
 AIRE, 272, 273
 Antigen receptor genes and V(D)J recombination
 about, 11–12
 conclusions, 18
 contraction and exclusion of antigen receptor loci, 12–13
 control by insulators, 16
 distribution of active chromatin at the *Igh* locus, 17–18, 19f
 extended *Igh* locus configuration, 16–17
 transcription factors and regulatory elements involved in locus contraction, 13–16
 V_H gene and mediation of locus contraction in pro-B cells, 17
 AREs (AU-rich elements), 51
 ARIADNE-2 (ARIH2), 141, 144–145
 Autoimmune diseases
 cytokines involved in the development of, 51
 microbiota's role in, 193, 199
 systems' approach to study of, 206–207
- B**
- BATF, 102–103
 B-cell receptor (BCR) signaling
 characteristics of memory B cells, 231–232
 early events in the initiation of, 232–234
 IgG BCRs in human MBCs, 231, 236
 mIgG and mIgM in the enhancement of MBC signaling, 234–236
- B-cells
 EBV pathologies and (*see* Epstein-Barr virus [EBV])
 identity determination (*see* B lymphopoiesis)
 IRF4 and IRF8 roles in B-cell development and activation, 101–102
 receptor signaling (*see* B-cell receptor [BCR] signaling)
 V_H gene and mediation of locus contraction in, 17
 Bcl11b, 33–35. *See also* T-cell lineage commitment
 BCR. *See* B-cell receptor (BCR) signaling
 BET (bromodomain and ET domain) family, 84, 86–87
 Biotin modification of 5hmC, 5
- B lymphopoiesis
 about, 23, 24f
 B cell lineage specification, 25–26
 conclusions, 27
 control of antigen diversity and (*see* V[D]J recombination)
 IRF4 and IRF8 roles in B-cell development and activation, 101–102
 mechanisms of EBF1 function in, 25, 26–27, 28f
 priming lymphoid development, 23–25
 regulators controlling B-cell specification, 44–45, 46
 repression of alternative cell fates, 26–27, 28f
- Brg1, 73, 75
 Bromodomain and ET domain (BET) family, 84, 86–87
- C**
- 5caC. *See* 5-Methylcytosine (5mC)
 CBM complex, 141
 CCCTC-binding factor (CTCF), 14, 16, 46
 CCL2 (mCP-1), 54
 CD (celiac disease), 205–207
 CD19 and T-cell immunity, 245
 CD45 phosphatase. *See* Csk and CD45 regulation of TCR signaling
 CD4 and CD8 T cells
 CD4⁺ and CD8⁺
 microbiota and host immunity and, 196–197
 TCR studies in immunology, 206
 concept of opposing actions on the same DC, 267–268
 DCs' presenting of selected sets of peptide/MHCs, 271
 DC-targeted regulation and selective peptide/MHCs presentation, 271–272
 enhancement of CD4 and CD8 responses by IL-18
 about, 117–118
 antigen-driven expansion of CD8 versus CD4 cells, 118–119
 conclusions, 123
 enhancement of the efficacy of weak vaccines, 122–123
 gene expression in OT-II cells undergoing IL-1-mediated expansion, 122
 impact on the frequency of OT-I and OT-II cells in response to immunization, 118–119
 impact on the function of CD4 and CD8 cells in response to antigen stimulation, 119–120, 121f
 secondary responses of mice primed with OVA and LPS, 120, 122
 evidence of selective regulation of CD4⁺ T-cell differentiation, 126
 governing of lymphopenia-induced proliferation and, 268–270
 lymphopenia and adjuvant effects of, 265–267
 model of CD4⁺ T-cell differentiation based on mTOR activation (*see* mTOR)
 modified model of CD4⁺ T-cell differentiation, 127–129
 programmed cell death and the process of exhaustion (*see* PD-1 [programmed cell death 1])
 regulation of responsiveness to self-peptide/MHCs by tuning, 273–274
 results of selection and random display of peptide/MHCs by DCs, 272–273
 results of T-cell production mutations, 272
 TCR repertoires of CD4 T cells and Tregs, 270–271
 Treg cells importance in expansion of, 267
 Celiac disease (CD), 205–207
 Cell-type identity. *See* T-cell lineage commitment
 Cellular senescence, 252–253, 254f
 ChAT (choline acetyltransferase), 145–146
Citrobacter rodentium, 194–195
Clostridia, 195, 196
 CLPs (common lymphoid progenitors), 23. *See also* B lymphopoiesis
 CLR signaling, 110
 Conserved noncoding sequence elements (CNS1, 2, 3), 217
 CpG islands (CGIs), 1, 67
 CpG methylation, 1

Csk and CD45 regulation of TCR signaling about TCR signaling, 131–132
 CD45 and Csk regulation of the basal state of T cells, 136
 CD45's counteraction of Csk function, 134–135
 conclusions, 137
 Csk inhibition's activation of SFKs, 133–134
 investigation of Csk activity, 133
 kinetic segregation model of TCR triggering, 137
 models of TCR activation, 131–132
 regulation of Lck phosphorylation by CD45, 135–136
 subcellular pools of Lck, 136–137
 CTCF (CCCTC-binding factor), 14, 16, 46
 CTLA-4 and T-cell immunity, 244
 CX₃CR1⁺ mononuclear phagocytes, 194–195
 CXXC domains, 2, 4
 CyTOF (cytometry by time of flight), 209–210

D

Dendritic cells (DCs)
 ARIADNE-2 and, 145
 concept of opposing actions on the same DC, 267–268
Myb-independent myeloid cells and, 94
 presenting of selected sets of peptide/MHCs, 271
 programming by IRFs, 103
 results of selection and random display of peptide/MHCs by, 272–273
 targeted regulation and selective peptide/MHCs presentation, 271–272
 therapeutic vaccinations and, 204, 244
 DNA methylation
 classes of DNMTs involved in, 1
 gene expression in T cells and, 5
 PD-1 and, 241–242
 TCR stimulation and, 216
 TET proteins and oxi-mC and, 3–4
 DNA methyltransferases (DNMTs)
 5-mC and, 1
 classes involved in DNA methylation, 1
 gene expression in T cells and DNA methylation, 5
 passive DNA demethylation, 3
 DSBH (double-strand β helix), 2
 Dysbiosis, 193. *See also* Microbiota

E

E2A and B-cell specification, 44–45, 46
 EAE (experimental autoimmune encephalomyelitis), 143
 EBF1, 25, 26–27, 28*f*. *See also* B lymphopoiesis
 Efflux pumps, 184–185
 E_μ enhancer, 14, 16
 Epstein-Barr virus (EBV)
 coevolution and coexistence with humans, 259
 conclusions, 261–262
 induction of immune surveillance and lymphomagenesis by LMP1, 259–260

modeling acute EBV infection in mice, 260–261
 ESX-1 mutant, 185–186
 Experimental autoimmune encephalomyelitis (EAE), 143

F

FACS (fluorescence-activated cell sorting), 209
 5*fc*. *See* 5-Methylcytosine (5mC)
 FoxO1, 25. *See also* B lymphopoiesis
 Foxp3⁺, 127–128
 Foxp3-expressing Treg cells
 conclusions, 220
 Foxp3-dependent program of Treg differentiation, 220–222
 induction regulation and Treg, 217
 microbiota tolerance and, 195
 Treg stabilization of Foxp3 expression, 217–218

G

G9a (histone methyltransferase), 82
 Genetics and the immune response. *See* Immunogenetics
 GPR15, 195
 GWASs (genome-wide association studies), 162–163

H

HAdV (human adenovirus), 84
 HEB, 45
Helicobacter hepaticus, 195
 Hematopoietic stem and progenitor cells (HSPCs), 29, 91
 Hematopoietic stem cells (HSCs), 91, 92
 Heterologous immunity, 207–208
 Histone methyltransferase G9a, 82
 Histone mimicry by pathogens
 about, 81–82
 antiviral response regulation by, 84, 85*f*
 conclusions, 87–88
 endogenous and exogenous, 82–84
 functional similarity between synthetic and natural histone mimics, 84, 86–87
 human pathogens with histone-like sequences, 87*f*
 structure and function of histone mimics, 83*f*
 Histone modifying enzymes, 18, 74–75, 87
 HIV
 genetic epidemiological studies involving, 162
 induction of NKG2D ligands and, 251
 IRF3-mediated signaling cross-interference and, 111–112
 MPTs and, 208–209
 PD-1 and HIV-specific CD8 cells, 241–242
 viral histone mimics and, 84
 5hmC, 4–5. *See also* 5-Methylcytosine (5mC)
 HSCs (hematopoietic stem cells), 91, 92
 HSPCs (hematopoietic stem and progenitor cells), 29, 91
 Human adenovirus (HAdV), 84

Human immunology
 celiac disease studies, 205–207
 gender-based differences in immune responses, 205, 206*f*
 immune surveillance of unhealthy cells (*see* NKG2D ligands system)
 limitations of current laboratory models, 203
 memory phenotype T cells in unexposed adults, 207–209
 systems approach to study, 203, 204–205
 technological developments in experimentation, 209–211

I

IDAX gene, 2, 4
 IELs (intestinal intraepithelial lymphocytes), 206
 IFNs (interferons), 105–107, 110, 113, 174–175. *See also* IRF (interferon-regulatory factor) family
 IgG BCRs in human MBCs, 231, 236
Igh and *Igk* genes. *See also* V(D)J recombination
 activity during B-cell development, 12–13, 23, 24, 27
 distribution of active chromatin at the *Igh* locus, 17–18, 19*f*
 early lymphocyte development and, 43, 44
 extended *Igh* locus configuration, 16–17
 Ikaros, 23, 25. *See also* B lymphopoiesis
 IKK ($\text{I}\kappa\text{B}$ kinase) complex, 55–57, 141
 IL-12 and IL-23 (interleukin-12 and 23)
 inducible gene transcription and, 61, 62
 inflammatory regulators and, 142, 143
 microbiota and host immunity and, 194, 195, 196, 199
 relationship to IRFs, 103, 111
Il12b gene. *See* Inducible gene transcription
 IL-1 and IL-6 and the immune response, 51. *See also* Regnase-1
 IL-1 β enhancement of T-cell responses about, 117–118
 antigen-driven expansion of CD8 versus CD4 cells, 118–119
 conclusions, 123
 enhancement of the efficacy of weak vaccines, 122–123
 gene expression in OT-II cells undergoing IL-1-mediated expansion, 122
 impact on the frequency of OT-I and OT-II cells in response to immunization, 118–119
 impact on the function of CD4 and CD8 cells in response to antigen stimulation, 119–120, 121*f*
 secondary responses of mice primed with OVA and LPS, 120, 122
 IL-1R-associated kinase 4 (IRAK4), 53
 IL-2 (interleukin-2)
 knockdown of Regnase-1 and, 57, 58
 promotion of T-cell responses during infection, 245
 Treg differentiation and, 215, 216, 218

SUBJECT INDEX

281

- Immune response in tuberculosis
conclusions and implications, 176
efficacy of the test for TB, 173
gaps in the understanding of, 173–174
prevalence of TB, 173
systems approaches to study of
about, 174
role of Type I IFN in
immunopathogenesis of TB,
174–176
strategy diagram, 175f
- Immune response regulation
human genetics and (*see*
Immunogenetics)
- inflammatory regulation response (*see*
LPS [lipopolysaccharide]
tolerance)
- IRFs and (*see* IRF [interferon-
regulatory factor] family)
- miR-181 and
conclusions, 226–228
miR-181 role as a nonredundant
metabolic rheostat, 225–226
PI3K and cellular metabolism,
223–224
PI3K/PTEN/miR-181 axis in
T-cell and NKT-cell
development, 226
PTEN and miRNA-mediated
regulation of cellular
metabolism, 224–225
redundancy in the miR-181
family, 226
- Regnase-1 role in
AREs and immune function, 51, 52
conclusions, 58–59
mRNA degradation pathways,
51–52
MyD88-IKK-independent
degradation of, 55–57
T-cell specific deletion of,
57–58
TLR family function and signaling,
52–53
Zc3h12a identification and
function, 53–55
- in TB (*see* Immune response in
tuberculosis)
- Immunogenetics
advancements in the tools of human
genetics, 157–158
clinical genetic studies
discovery of essential functions
of known genes, 160–161
discovery of new genes, 159–160
general concepts and methods, 158
identification of new functions for
known genes, 160
locus, allelic, and phenotypic
heterogeneity, 158–159
conclusions, 165–166
evolutionary genetics in humans
essentiality and, 163–164
general concepts and methods, 163
immunological redundancy and,
164
improving gene function and,
164–165
side effects of past selection and,
165
genetic epidemiological studies
candidate gene association studies,
162
general concepts and methods, 161
- genome-wide association studies,
162–163
linkage studies, 161–162
search for missing heritability, 163
modern approaches to molecular
genetics, 158
- Immunoglobulin heavy chain locus (*Igh*).
See Igh and *Igk* genes
- Inducible gene transcription
biological basis of nucleosome
remodeling requirements,
65–66
conclusions, 67
Il12b transcriptional induction
studies, 62
mechanistic basis of nucleosome
remodeling requirements,
64–65
nucleosome remodeling at *Il12b*
regulatory regions, 62–63
nucleosome remodeling by SWI/SNF
complexes, 63–64
RNA-sequencing analysis of, 66–67
role of SWI/SNF complexes, 64
specificity of transcriptional responses
and, 61
- Inflammatory regulators
about, 141–142
ACh, 145–146
ARIADNE-2, 141, 144–145
conclusions, 146
MALT1, 141, 142–144
NF- κ B activation pathway, 141, 142f
- Inflammatory response and LPS tolerance
about, 69
chromatin remodeling and miRNA,
74–75
conclusions, 75–76
cross-tolerance, 71
histone modifying enzymes as a
regulatory target, 75
hyperresponsive genes in, 71
inclusive model for, 73
late response genes and, 72–73
NF- κ B activation and, 69–70
regulation by miRNAs, 73–74, 75
SWI/SNF complex as a regulatory
target, 75
- TLR4 signaling and, 69, 70–71
Tnf and *Il1b* promoters and, 71–72
in vivo studies, 70
- Inhibitor of κ B (*I κ B*), 141
- Interferon regulatory family. *See* IRF
- Interferons (IFNs), 105–107, 108, 110,
174–175. *See also* IRF
(interferon-regulatory factor)
family
- Intergenic control region 1 (IGCR1), 16
- Interleukins. *See* IL-1 β enhancement of
T-cell responses; IL-2; IL-12
and IL-23
- Intestinal intraepithelial lymphocytes
(IELs), 206
- Ip of the 5hmC derivative CMS method
(CMS-IP), 6, 7
- IRAK4 (IL-1R-associated kinase 4), 53
- IRF (interferon-regulatory factor) family
about, 105–106
CLR signaling and, 110
conclusions, 113
cross-interaction between PRR
signaling and, 111–113
in cytosolic DNA sensor signaling,
107–108
- induction of cytosolic PRR signaling in
type I IFN, 106, 107f
- interaction with other transcription
factors, 110–111
- IRF4 and IRF8's regulation of the
immune response
B-cell development and activation
roles, 101–102
conclusions, 104
dendritic cell programming roles,
103
evidence of new modes of DNA
assembly and, 103–104
immune system roles, 101
regulation of helper-T-cell
differentiation and, 102–103
- NF- κ B activation
hyporesponsiveness of Tnf
transcription and, 72
interactions with IRFs, 110–111
LPS tolerance and, 69–70, 73
pathways for, 141, 142f
signaling and ARIADNE-2, 145
signaling and MALT1, 142–144
- NLR signaling and, 110
in RLR signaling, 106–107
in TLR signaling
MyD88-dependent pathway and,
108–110
TRIF-dependent pathway and, 108,
109f
- ## J
- Janeway, Charles A., 117, 125, 265
- Janeway synthesis, 265
- ## L
- LAG-3 and T-cell immunity, 243
- Latent membrane proteins (LMPs)
conclusions, 261–262
induction of EBV immune surveillance
and lymphomagenesis by,
259–260
modeling acute EBV infection in mice
and, 260–261
- Lck, 131, 135–136. *See also* T-cell
receptor (TCR)
- Lipopolysaccharide. *See* LPS
(lipopolysaccharide) tolerance
- Liver NK cells, 151
- Liver-resident NK cells, 151–152
- LMPPs (lymphoid-primed multipotent
progenitors), 23. *See also* B
lymphopoiesis
- LMPs (latent membrane proteins)
conclusions, 261–262
induction of EBV immune surveillance
and lymphomagenesis by,
259–260
modeling acute EBV infection in mice
and, 260–261
- LMRs (low-methylated regions), 1
- LPS (lipopolysaccharide) tolerance
about, 69
chromatin remodeling and miRNA,
74–75
conclusions, 75–76
cross-tolerance, 71
histone modifying enzymes as a
regulatory target, 75
hyperresponsive genes in, 71

LPS (lipopolysaccharide) tolerance
(*Continued*)
inclusive model for, 73
late response genes and, 72–73
NF- κ B activation and, 69–70
regulation by miRNAs, 73–74, 75
SWI/SNF complex as a regulatory target, 75
TLR4 signaling and, 69, 70–71
Tnf and Il1b promoters and, 71–72
transcription induction studies using, 62
in vivo studies, 70

Lymph node NK cells, 150

Lymphocyte development
conclusions, 47
early hematopoiesis and, 43–44
function of anchors, 47
lymphoid genome topology charting, 46–47
models describing long-range chromatin architecture, 43
transcriptional control of, 44–45
transcription factor occupancy and, 45–46

Lymphoid-primed multipotent progenitors (LMPPs), 23. *See also* B lymphopoiesis

M

Macrophages. *See* Myb-independent macrophages

Major histocompatibility complexes (MHCs), 125, 149, 265, 271–274

MALT1, 141, 142–144

MBCs (memory B cells), 231, 234–236.
See also B-cell receptor (BCR) signaling

MCP-1 (CCL2), 54

Mechanistic target of rapamycin. *See* mTOR

Membrane IgG (mIgG), 231. *See also* B-cell receptor (BCR) signaling

Memory phenotype T cells (MPTs), 207–209

Methylated DNA-IP (MeDIP), 5

5-Methylcytosine (5mC)
about, 1
biological functions of 5hmC, 4–5
biological functions of TET proteins, 4
conclusions, 7–8
detection and mapping of 5mC and oxi-mC
affinity approaches, 5–6
sequencing depth's effect on mapping performance, 7
single-nucleotide resolution approaches, 6–7
distribution mapping of, 1
gene expression in T cells and, 5
relationship to DNMTs, 1
TET proteins and generation of 5mC oxidases, 1–2
TET proteins and oxi-mC
active DNA methylation through DNA repair, 3–4
demethylation pathways and, 2–3
passive dilution of the oxidized base during replication, 3

MHCs (major histocompatibility complexes), 125, 149, 265, 271–274

Microbiota
conclusions, 199–200
contribution of Treg cells to intestinal barrier function, 195
CX₃CR1⁺ mononuclear phagocytes' role in compartmentalization of, 194–195
homeostatic induction of effector T cells, 195–198
intestinal immunity role, 193, 194f
role in human autoimmune disease, 193, 199

mIgG (membrane IgG), 231. *See also* B-cell receptor (BCR) signaling

miR-181 and metabolic regulation
conclusions, 226–228
miR-181 role as a nonredundant metabolic rheostat, 225–226
PI3K and cellular metabolism, 223–224
PI3K/PTEN/miR-181 axis in T-cell and NKT-cell development, 226
PTEN and miRNA-mediated regulation of cellular metabolism, 224–225
redundancy in the miR-181 family, 226

miRNAs (microRNAs)
influence on chromatin regulators, 74–75
regulation of LPS tolerance by, 73–74
roles in the outcome of stimulation, 75

MPS (mononuclear phagocyte system), 91–92

MPTs (memory phenotype T cells), 207–209

mRNA
induction of Zc3h12a, 53–55
miRNAs and, 73
Regnase-1 and, 51–52, 56–58
regulation of NKG2D, 251–252
regulation of NKG2D at the mRNA level, 251–252
SWI/SNF complexes investigations and, 63–64
TET proteins and, 4, 5
in transcriptional kinetics analyses, 66

mTOR (mechanistic target of rapamycin)
about, 125, 126
conclusions, 129
evidence of selective regulation of CD4⁺ T-cell differentiation, 126
linking of T-cell activation with metabolic programs, 126
model of TCR engagement and the immune response, 125–126
modified model of CD4⁺ T-cell differentiation, 127–129
tracking cell fate using, 126–127

Mucosa-associated lymphoid tissue (MALT) lymphoma translocation gene 1, 141, 142–144

Myb-independent macrophages
bone marrow radiation chimera and, 93–94
conclusions, 97
dendritic cells and, 94
evidence of self-renewal independent from bone marrow, 92
functional differences from BM-derived myeloid cells, 96–97
monocytes as effector cells, 94
mononuclear phagocyte system and, 91–92

origination and FLT3-independence, 92–93
origination from extraembryonic progenitors, 95–96
origins of, 92, 95–97
persistence due to cell proliferation, 93
potentials of the hematopoietic precursors, 95

Mycobacterium marinum - zebrafish model, 180. *See also* Zebrafish tuberculosis study

Mycobacterium tuberculosis, 173. *See also* Tuberculosis

MyD88-dependent pathway
activation of pro-inflammatory gene induction, 111
degradation of Regnase-1, 55–57
essentiality of, 164
induction of Zc3h12a and, 53–55
LPS tolerance and, 53–55, 69, 70
TLR signaling and, 52–53, 108–110, 144–145, 182, 184
in tuberculosis studies, 182

N

nAChR (nicotinic acetylcholine receptors), 142

Natural killer cells. *See* NK cells

NF- κ B activation
hyporesponsiveness of Tnf transcription and, 72
interactions with IRFs, 110–111
LPS tolerance and, 69–70, 73
pathways for, 141, 142f
signaling and ARIADNE-2, 145
signaling and MALT1, 142–144

Nicotinic acetylcholine receptors (nAChR), 142

NK (natural killer) cells
about, 149
conclusions, 154
conventional NK-cell development, 149–150
immune surveillance of unhealthy cells by (*see* NKG2D ligands system)
liver, 151
liver-resident, 151–152
lymph node, 150
PI3K/PTEN/miR-181 axis in T-cell and NKT-cell development, 226
thymic, 150–151
tissue-resident, 152–154
uterine, 150

NKG2D ligands system
about, 249–250
conclusions, 255
regulation at the mRNA level, 251–252
regulation at the protein level, 252
transcriptional regulation of, 250–251
tumor suppression mechanism's link to the immune response, 252–253, 254f, 255

NLR signaling, 110

Norverapamil, 185

Notch-Delta interaction, 31–33, 34

NS1 (nonstructural protein 1), 82–84

Nucleosome remodeling, 63–66

O

Omenn syndrome, 272

OT-I and OT-II cells

- antigen-driven expansion of CD8
versus CD4 cells and, 118–119
- gene expression in cells undergoing
IL-1-mediated expansion, 122
- impact of IL-1 β on the frequency of in
response to immunization, 119
- impact of the addition of IL-1 β on cell
expression, 119–120, 121*f*
- secondary responses of mice primed
with OVA and LPS, 122
- Oxidative bisulfite sequencing (oxBS), 7
- Oxidative phosphorylation (OXPHOS), 223
- Oxi-mC
detection and mapping of 5mC and
affinity approaches, 5–6
- sequencing depth's effect on
mapping performance, 7
- single-nucleotide resolution
approaches, 6–7
- TET proteins and
active DNA methylation through
DNA repair, 3–4
- demethylation pathways and, 2–3
- passive dilution of the oxidized
base during replication, 3
- OXPHOS (oxidative phosphorylation), 223
- P**
- p53 and tumor suppression, 252–253,
254*f*, 255
- Paf1, 84, 85*f*
- PAIR (pax5-activated intergenic repeat),
14–16
- PAMPs (pathogen-associated molecular
patterns), 182
- Pattern-recognition receptors (PRRs),
105–106, 107*f*, 111–113
- Pax5, 25, 26–27, 28*f*. *See also* B
lymphopoiesis
- Pax5-activated intergenic repeat (PAIR),
14–16
- PD-1 (programmed cell death 1)
about, 239
- conclusions, 245
- DNA methylation and, 241–242
- efficacy of PD-1 blockade in
combination therapy
adoptive immunotherapy, 245
- basis of, 242–243
- blockade of other inhibitory
receptors, 243–244
- modulating cytokine signals,
244–245
- therapeutic vaccination, 243
- epigenetic regulation of PD-1 gene
expression, 239–242
- potential mechanisms of directed
therapy, 242, 243*f*
- role in T-cell exhaustion during chronic
viral infection, 242
- PDIMs (phthiocerol dimycocerosates), 182
- Peptide/MHCs, 271–274
- Phosphatidylinositol 3-kinase pathway. *See*
PI3K
- PI3K pathway
cellular metabolism and, 223–224
- PI3K/PTEN/miR-181 axis in T-cell
and NKT-cell development, 226
- PTEN and miRNA-mediated regulation
of cellular metabolism,
224–225
- Prevotella copri*, 199
- Pro-B cells, 17
- Programmed cell death 1. *See* PD-1
- PRR signaling, 105–106, 107*f*, 111–113
- PTEN
miRNA-mediated regulation of cellular
metabolism and, 224–225
- PI3K/PTEN/miR-181 axis in T-cell
and NKT-cell development, 226
- PU.1
changes in expression in during T-cell
lineage commitment, 33
- contribution to phase 1 regulatory state
of T-cell development, 36
- dominant-negatives and gain of
function, 37–38
- function and role in B lymphopoiesis,
23, 24, 25
- IRF4 and IRF8 roles in B-cell develop-
ment and activation, 101–102
- role in phase 1 regulatory functions,
36–38
- R**
- RA (rheumatoid arthritis), 193, 199
- Regnase-1 (regulatory RNase-1)
AREs and immune function, 51, 52
- conclusions, 58–59
- mRNA degradation pathways, 51–52
- MyD88-IKK-independent degradation
of, 55–57
- T-cell specific deletion of, 57–58
- TLR family function and signaling,
52–53
- Zc3h12a identification and function,
53–55
- Regulatory T cells. *See* Treg cells
- Responsiveness-tuning, 265, 275
- Rheumatoid arthritis (RA), 193, 199
- RLR signaling, 106–107
- RNA-sequencing analysis, 66–67
- S**
- SCID (severe combined immunodeficien-
cy), 160
- Sequencing and mapping performance, 7
- SFB (spore-forming anaerobe), 196–198
- SFK (Src family tyrosine kinase), 131
- Short linear motifs (SLiMs), 81
- Single-nucleotide resolution approaches to
mapping 5mC, 6–7
- SLiMs (short linear motifs), 81
- STAT5, 218
- STORM microscopy, 236
- SWI/SNF complexes
biological basis of nucleosome remod-
eling, 65–66
- mechanistic basis of nucleosome re-
modeling, 64–65
- nucleosome remodeling by, 63–64
- as a regulatory target, 75
- role at inducible genes, 64
- T**
- T-cell lineage commitment
Bcl11b regulation and, 34–35
- conclusions, 38–39
- contribution of PU.1 to phase 1 regula-
tory state, 36
- early T-cell development outline, 32*f*
- Notch signals and stem cell fate deter-
mination, 31–33
- PU.1 dominant-negatives and, 37–38
- regulation of helper-T-cell differentia-
tion by IRF4-BATF complex,
102–103
- repression of Phase 1 regulatory genes
and, 35–36
- role of Bcl11b in commitment, 33–34
- role of PU.1 in phase 1 regulatory
functions, 36–38
- stem cell multipotentiality and, 31
- T-cell specific deletion of Regnase-1,
57–58
- T-cell receptor (TCR)
celiac disease studies and, 205–207
- Csk and CD45 regulation of signaling
about TCR signaling, 131–132
- CD45's counteraction of Csk
function, 134–135
- conclusions, 137
- Csk inhibition's activation of
SFKs, 133–134
- investigation of Csk activity, 133
- kinetic segregation model of TCR
triggering, 137
- models of TCR activation,
131–132
- regulation of Lck phosphorylation
by CD45, 135–136
- regulation of the basal state of
T cells, 136
- subcellular pools of Lck, 136–137
- guidance of the outcome of recognition
(*see* mTOR)
- role of activation in Treg-cell
transcription, 216
- T-cells
differentiation model (*see* mTOR)
- enhancement of CD4 and CD8
responses by IL-1 β
about, 117–118
- antigen-driven expansion of CD8
versus CD4 cells, 118–119
- conclusions, 123
- enhancement of the efficacy of
weak vaccines, 122–123
- gene expression in OT-II cells
undergoing IL-1-mediated
expansion, 122
- impact on the frequency of OT-I
and OT-II cells in response to
immunization, 118–119
- impact on the function of CD4 and
CD8 cells in response to anti-
gen stimulation, 119–120, 121*f*
- secondary responses of mice
primed with OVA and LPS,
120, 122
- gene expression and 5mC, 5
- gene expression and DNA
methylation, 5
- immune response (*see* CD4 and CD8 T
cells)
- mechanisms of TCR triggering (*see* Csk
and CD45 regulation of TCR
signaling)
- memory phenotype T cells in
unexposed adults, 207–209

- T-cells (*Continued*)
 regulation of responses and
 differentiation (*see* Treg cells)
 regulation of T-cell exhaustion
 about PD-1, 239
 conclusions, 245
 DNA methylation and PD-1,
 241–242
 efficacy of PD-1 blockade in
 combination therapy, 242–245
 epigenetic regulation of PD-1 gene
 expression, 239–242
 PD-1's role during chronic viral
 infection, 242
 potential mechanisms of directed
 therapy, 242, 243*f*
 specificity of development (*see* T-cell
 lineage commitment)
 transcriptional control of regulatory
 T-cell differentiation,
 215–220
- TCRB, 45
- TDG (thymine DNA glycosylase), 3–4
- TET-assisted BS-seq, 7
- TET proteins
 biological functions of, 4
 gene expression in T cells and, 5
 generation of 5mC oxidases and, 1–2
 oxi-mC and demethylation pathways,
 2–4
- Th1 and Th17 cells
 induction of T-cell response and,
 111–113
 investigations into MALT1 and,
 143–144
 SFB in microbiota and Th17, 196–198
 T-cell differentiation and, 126, 224
- Thymic NK cells, 150–151
- Thymine DNA glycosylase (TDG), 3–4
- Tim-3 and T-cell immunity, 243–244
- Tissue-resident NK cells, 152–154
- TLR (toll-like receptor) signaling
 essentiality of, 160, 163, 164
 immunological redundancy and, 164
 interaction with IRFS, 110–113
 LPS tolerance and TLR4, 69–71, 73, 74
 MyD88-dependent pathway and,
 52–53, 108–110, 144–145,
 182–184
 transcriptional induction and, 61, 62, 63
 TRIF-dependent pathway and, 108,
 109*f*
- Transcription start sites (TSSs), 1
- Treg cells
 about, 215
 conclusions, 220
 contribution to intestinal barrier
 function, 195
 Foxp3-dependent program of Treg
 differentiation, 220–222
 Foxp3-independent program of
 differentiation, 215–216
 inflammatory regulators
 about, 141–142
 ACh, 145–146
 ARIADNE-2, 141, 144–145
 conclusions, 146
- MALT1, 141, 142–144
- NF- κ B activation pathway, 141,
 142*f*
- regulation of
 concept of opposing actions on the
 same DC, 267–268
 DCs' presenting of selected sets of
 peptide/MHCs, 271
 DC-targeted regulation and
 selective peptide presentation,
 271–272
 governing of lymphopenia-induced
 proliferation, 268–270
 Janeway synthesis and, 265
 lymphopenia and adjuvant effects
 of CD4 T cells, 265–267
 regulation of responsiveness to
 self-peptide/MHCs by tuning,
 273–274
 results of selection and random
 display of peptide/MHCs by
 DCs, 272–273
 results of T-cell production
 mutations, 272
 summary, 274–275
 TCR repertoires of CD4 T cells and
 Tregs, 270–271
 tolerance and the distinction of self
 from non-self, 273
 regulation of Foxp3 induction, 217
 stabilization of Foxp3 expression,
 217–218
 transcription factors essential to
 stability, 218
- TRIF, 53, 55–57, 164
- TRIF-dependent pathway, 108, 109*f*, 111
- TSSs (transcription start sites), 1
- TTP (tristetraprolin), 52
- Tuberculosis
 immune response in
 conclusions and implications, 176
 efficacy of the test for TB, 173
 gaps in the understanding of,
 173–174
 prevalence of TB, 173
 systems approaches to study of,
 174–176, 175*f*
 pathogenesis of, 179–180
 status of effectiveness of therapies
 against, 179
- in zebrafish
 conclusions, 189
 experimental process for infecting
 zebrafish, 180–181, 182*f*
 interaction of pathogenic
 mycobacteria with permissive
 macrophages, 182–184
 macrophage role in mycobacterial
 drug tolerance, 184–185
 M. marinum - zebrafish model
 appropriateness, 180, 181*f*
 mycobacterial recruitment of
 macrophages, 185–187
 TNF's role in hypersusceptibility,
 187–189
- Type I IFN-inducible genes, 53, 174–176.
See also IFNs (interferons)
- U
- UHRF1, 1
- UMRs (unmethylated regions), 1
- Uterine NK cells, 150
- V
- Vaccines
 enhancement of the efficacy of weak
 vaccines, 122–123
 systems approach study of, 204–205
- Vagus nerve, 142
- V(D)J recombination
 about, 11–12
 conclusions, 18
 contraction and exclusion of antigen
 receptor loci, 12–13
 control by insulators, 16
 distribution of active chromatin at the
 Igh locus, 17–18, 19*f*
 extended *Igh* locus configuration,
 16–17
 transcription factors and regulatory
 elements involved in locus
 contraction, 13–16
 V_H gene and mediation of locus
 contraction in pro-B cells, 17
- Verapamil, 184–185
- V_H gene cluster, 11, 17. *See also* V(D)J
 recombination
- Viral histone mimics
 about, 81–82
 antiviral response regulation by,
 84, 85*f*
 conclusions, 87–88
 endogenous and exogenous, 82–84
 functional similarity between synthetic
 and natural histone mimics, 84,
 86–87
 human pathogens with histone-like
 sequences, 87*t*
 structure and function of histone
 mimics, 83*f*
- Z
- ZAP-70, 131. *See also* T-cell receptor
 (TCR)
- Zc3h12a, 53–55
- Zebrafish tuberculosis study
 conclusions, 189
 experimental process for infecting
 zebrafish, 180–181, 182*f*
 interaction of pathogenic mycobacteria
 with permissive macrophages,
 182–184
 macrophage role in mycobacterial drug
 tolerance, 184–185
 M. marinum - zebrafish model
 appropriateness, 180, 181*f*
 mycobacterial recruitment of
 macrophages, 185–187
 TNF's role in hypersusceptibility,
 187–189

Cold Spring Harbor Symposia on Quantitative Biology

Subject Index

Cold Spring Harb Symp Quant Biol 2013 78: 279-284

Access the most recent version at doi:[10.1101/sqb.2013.78.SI](https://doi.org/10.1101/sqb.2013.78.SI)

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>